Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Inclusion Criteria

• •Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
• •Locally advanced stage IIIA or IIIB disease that is considered unresectable
• •No stage IV disease
• •Requires radiotherapy
• •Performance status (PS) - Eastern Cooperative Oncology Group (ECOG) 0-1
• •At least 12 weeks
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •aspartate aminotransferase (AST) ≤ 3 times ULN
• •Creatinine ≤ 1.5 times ULN
• •No New York Heart Association class III or IV heart disease
• •Forced expiratory volume (FEV) FEV\_1 ≥ 1 L OR 35% of predicted
• •Weight loss \< 10% within the past 3 months
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No peripheral neuropathy ≥ grade 2
• •No other severe underlying disease that would preclude study participation
• •No uncontrolled infection
• •No unhealed wound within the past 2 weeks
• •No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas (carcinoma in situ), or localized prostate cancer
• •No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)
• •No prior systemic chemotherapy for NSCLC\*
• •No prior radiotherapy to the chest
• •More than 2 weeks since prior major surgery
• •Contraindications
• •Any of the following:
• •* Pregnant wome
• •* Nursing women
• •* Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], or abstinence, etc.) as this regimen may be harmful to a developing fetus or nursing child NOTE: This study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown.
• •Any of the following prior therapies:
• •* Prior radiation therapy to the chest
• •* Prior systemic chemotherapy for NSCLC (phase II portion)
• •New York Heart Association classification III or IV (see Appendix II).
• •Any other severe underlying diseases which are, in the judgment of the investigator, inappropriate for entry into this study.
• •uncontrolled infection.
• •Major surgery or unhealed wound ≤ 2 weeks prior to registration.
• •Prior history of malignancy ≤ 5 years, except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas (carcinoma in situ), or localized prostate cancer.
• •Peripheral neuropathy ≥grade 2